文献速递淋巴瘤

TRANSCAR:CD19 CAR-T细胞治疗复发/难治性转化惰性淋巴瘤的真实世界结局

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas.
PubMed 文献 · Blood Adv · 2025-01-01

基于法国DESCAR-T登记处4个中心的数据,经专家病理复核确认的转化惰性非霍奇金淋巴瘤(TriNHL,N=110)与新生大B细胞淋巴瘤(LBCL,N=391)接受CD19 CAR-T细胞治疗。1:1倾向性评分匹配后(n=170,TriNHL 85例,新生LBCL 85例),TriNHL组1年无进展生存率55.8%优于新生LBCL组31.7%(HR 0.54,P=0.0034),1年总生存率72.1%优于50.7%(P=0.031),毒性无差异。

要点

  • 匹配后TriNHL组1年无进展生存率55.8%优于新生LBCL组31.7%(HR 0.54,P=0.0034)。
  • TriNHL组1年总生存率72.1%优于新生LBCL组50.7%(P=0.031)。
  • 两组毒性无差异,逆概率加权分析结果相似。

核心结论

  • 匹配比较研究显示,TriNHL患者接受CAR-T细胞治疗的疗效优于新生LBCL患者,且毒性特征与新生LBCL患者相当。

研究设计与样本

  • 来自法国DESCAR-T登记处4个中心的真实世界研究,TriNHL组N=110,新生LBCL组N=391。
  • 经专家病理复核(LYMPHOPATH)确认TriNHL,采用1:1倾向性评分匹配(n=170,TriNHL 85例,新生LBCL 85例)。

主要发现

  • TriNHL组中位随访19.4个月(95%CI 12.0-25.1),新生LBCL组中位随访18.5个月(95%CI 13.8-24.8)。
  • 1年无进展生存率TriNHL组55.8%(95%CI 43.6-66.4)优于新生LBCL组31.7%(95%CI 21.4-42.6),HR 0.54(95%CI 0.36-0.82),P=0.0034。
  • TriNHL组最佳总缓解率82.4%、完全缓解率63.5%,新生LBCL组分别为63.5%和50.6%。
  • 1年总生存率TriNHL组72.1%(95%CI 59.6-81.4)优于新生LBCL组50.7%(95%CI 38.2-62.0),P=0.031。
  • 逆概率加权统计方法得到相似结果,两组毒性无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD19 chimeric antigen receptor (CAR) T cells have shown impressive results in the treatment of relapsed/refractory aggressive large B-cell lymphomas (LBCLs). However, the prognostic value of the LBCL histological subtype in the context of CAR T-cell therapy is unclear. Here, we report the prognostic value of transformed indolent non-Hodgkin lymphoma (TriNHL; N = 110) confirmed by an expert pathological review (LYMPHOPATH) vs de novo LBCL (N = 391) in the context of CAR T-cell therapy from 4 centers of the French DESCAR-T registry. After 1:1 propensity score matching (n = 170, 85 patients with TriNHL and 85 patients with de novo LBCL), the median follow-up was 19.4 months (95% confidence interval [CI], 12.0-25.1) for patients with TriNHL and 18.5 months (95% CI, 13.8-24.8) for patients with LBCL. The 1-year progression-free survival rate was significantly better (55.8%; 95% CI, 43.6-66.4) in the TriNHL group than in the de novo LBCL group (31.7%; 95% CI, 21.4-42.6; hazard ratio, 0.54; 95% CI, 0.36-0.82; P = .0034). The best overall response rate and complete response rate were 82.4% and 63.5%, respectively, whereas they were 63.5% and 50.6%, respectively, for the TriNHL group compared with the de novo LBCL group. The 1-year overall survival was also longer in the TriNHL group than in the de novo LBCL group (72.1%, [95% CI, 59.6-81.4] vs 50.7%, [95% CI, 38.2-62.0]; P = .031). Similar findings were found via an inverse probability weighting statistical approach. No difference was observed in terms of toxicity. In conclusion, our matched-comparison study revealed a greater efficacy of CAR T-cell therapy, with a toxicity profile for patients with TriNHL comparable with that for patients with LBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stephan P, Di Blasi R, Roulin L, et al. TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas. Blood Adv. 2025. PMID: 40311067. doi:10.1182/bloodadvances.2025015834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。